

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	31.5	63.4	(38.7-98.0)	Male	18	19.2	93.5	(55.4-147.8)
Female	6	10.6	56.4	(20.6-122.8)	Female	13	14.1	91.9	(48.9-157.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.6	142.3	(61.3-280.5)	Male	7	6.1	114.0	(45.7-235.0)
Female	5	4.5	110.4	(35.6-257.6)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	17.2	134.1	(85.0-201.2)
Female	132	116.4	113.4	(94.9-134.5)	Female	14	14.6	96.0	(52.5-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	10	13.3	75.0	(35.9-138.0)
<u>Colon / Rectum</u>					Female	5	6.1	81.8	(26.4-190.8)
Male	26	32.7	79.6	(52.0-116.6)	<u>Ovary</u>				
Female	26	30.5	85.4	(55.7-125.1)	Female	8	9.9	80.8	(34.8-159.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.6	nc	(nc-nc)	Male	18	10.8	166.8	(98.8-263.6)
Female	0	2.1	nc	(nc-nc)	Female	7	10.7	65.3	(26.2-134.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	89	85.5	104.0	(83.6-128.0)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	7.4	nc	(nc-nc)
Male	17	15.9	106.7	(62.1-170.9)	Female	3	4.1	nc	(nc-nc)
Female	5	9.3	53.7	(17.3-125.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	10	7.1	141.0	(67.5-259.4)
<u>Leukemia</u>					Female	28	20.9	134.0	(89.0-193.6)
Male	16	12.3	129.6	(74.0-210.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.4	59.7	(19.2-139.3)	Female	32	25.5	125.4	(85.8-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.9	100.8	(48.3-185.4)	Male	366	381.0	96.1	(86.5-106.4)
Female	3	3.4	nc	(nc-nc)	Female	383	391.3	97.9	(88.3-108.2)
<u>Lung and Bronchus</u>									
Male	41	54.8	74.8	(53.7-101.5)					
Female	55	57.2	96.2	(72.5-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;